The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.

Head and neck cancer comprises a group of biologically similar cancers that start in the lip, oral cavity (mouth), nasal cavity (inside the nose), paranasal sinuses, pharynx and larynx.

The trial, which was funded by MSD (Merck & Co., Inc., Rahway, NJ, USA) and led by researchers at Washington University School of Medicine in St. Louis, MO, USA, tested the drug in patients with newly ...